Medication info
Emploem Sustained Release Tablet 5/1000 mg (Empagliflozin, Metformin)

Emploem Sustained Release Tablet 5/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
White and light green, double convex oval sustained-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500551 · Approved 2025.03.12 · Insurance code 645907600

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. Take this medicine once daily with a meal in the evening to reduce gastrointestinal adverse reactions caused by metformin. Take one 10/1000 mg or 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medicine must be discontinued immediately. In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control issues
  • cardiovascular disease
View approved original text

This medication is used to assist in blood sugar control for adult patients with type 2 diabetes when combined with dietary and exercise regimens. It is particularly effective when blood sugar is not adequately controlled, increasing its efficacy by combining Empagliflozin with Metformin. It is also used in patients with confirmed cardiovascular disease, and precautions regarding cardiovascular events should refer to professional information. Therefore, this medication helps improve blood sugar control and manage cardiovascular risk in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. Take this medicine once daily with a meal in the evening to reduce gastrointestinal adverse reactions caused by metformin. Take one 10/1000 mg or 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medicine must be discontinued immediately. In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Precautions

This medication is used for the treatment of diabetes and contains two main ingredients: Empagliflozin and Metformin. It can occasionally cause serious side effects such as lactic acidosis, so it should not be used by individuals with poor kidney function, serious infections, or heart issues. Additionally, caution is needed as hypoglycemia may occur if taken with insulin or sulfonylurea medications. Regular checks of kidney function should be conducted, and if kidney function declines, this medication should be discontinued. In situations where there is a risk of fluid loss, such as severe vomiting, diarrhea, or dehydration, it is advisable to temporarily halt the use of this medication. This drug should not be used by patients with impaired liver function, pregnant women, or those with certain genetic lactase deficiencies. While on this medication, urinary tract infections or genital infections may occur; if symptoms of infection arise, notify healthcare providers immediately. Furthermore, vitamin B12 levels may decrease, so it is recommended to check vitamin B12 status through blood tests during prolonged use. The medication should be temporarily discontinued before any surgeries or diagnostic tests using radiocontrast agents and started again only after confirming normal kidney function post-test. The risk may increase when taken with alcohol, so excessive drinking should be avoided during treatment. Elderly patients or those with reduced fluid volume should be monitored for low blood pressure or dehydration risk. This medication should be swallowed whole without chewing or crushing, and it is normal for the tablet coating to appear in stool. In case of overdose, medical attention should be sought immediately, as serious side effects such as lactic acidosis may occur.

Side effects

  • severe lactic acidosis
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased vitamin B12 and deficiency
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • nausea
Show 158 more
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vaginismus
  • vulvovaginitis
  • balanitis
  • perineal necrosis
  • decreased blood sugar
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • liver damage
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic cancer
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colon bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • adnexal-ovarian abscess
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • cervicitis
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal deposits
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • senile dyspnea
  • productive cough
  • allergic rhinitis
  • residual sputum
  • skin laceration
  • rib fracture
  • ligamentum flavum syndrome
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • insomnia
  • vulvar pruritus
  • genital pruritus
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage will help keep the medication effective for a longer time.

Appearance and packaging

Appearance

White and light green, double convex oval sustained-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.